20 May 05
In addition to the traditional clinical needs, such as efficacy and resistance profile, product characteristics such as dosing and side effects can be fundamental in maintaining market share in the maturing antiretroviral market. In response to the launch of two once-daily protease inhibitors (PI), Abbott has reformulated its leading PI drug, Kaletra (lopinavir/ritonavir) in a once-daily dose.
18 May 05
With UK MP’s, Committees, Regulatory bodies, Health Services and Companies looking for someone to blame for the dangers of patient non-compliance and drug safety issues it’s time to learn how the simplest technology can deliver the biggest rewards and bring you closer to your patients.
29 Apr 05
The Healthcare Industry is currently experiencing the effects of a global shortage of qualified and experienced clinical research professionals – and this situation has evolved into the industry’s very own version of ‘Catch 22’. While employers are looking to hire candidates who are already experienced in the practice of clinical research, new Life Science graduates and others wishing to start on a career in the Healthcare Industry are unable to gain such experience without first being hired.
European Director CRAcademy
16 Mar 05
Depression is the most common mental disorder worldwide affecting around 120 million people globally. The depression market is the largest segment of the CNS market with global sales of US$15.5 billion in 2003 although this figure is dropping as generic equivalents of past blockbusters are launched. Although the depression market has matured, key areas of unmet clinical need will have to be addressed in order to drive further growth of the market. These include improvements in the safety/tolerab
16 Mar 05
According to the WHO, 350-400 million individuals are chronically infected with the hepatitis B virus (HBV). Chronic infection with hepatitis viruses causes cirrhosis and hepatocellular carcinoma, both devastating diseases with few treatments and the demand for effective treatments for hepatitis infection is therefore high. Lamivudine dominates first-line therapy for HBV (see our feature on hepatitis B & C). Gilead's Adefovir prodrug (Hepsera) represent a second line option although nephrotoxici
16 Mar 05
Beta blockers reduce heart rate and myocardial contractility thereby reducing myocardial work load. Diastolic perfusion time is also lengthened by beta blockers supporting the use of this drug class as acute and chronic treatment following myocardial infarction. Studies have demonstrated that beta blockers can reduce total mortality, nonfatal myocardial infarction and sudden death in patients who have already suffered a myocardial infarction by 20-30%. Despite the potential benefit of beta block
16 Mar 05
Lupus is a chronic inflammatory disease that can affect various parts of the body, especially the skin, joints, blood, and kidneys. For most people, lupus is a mild disease affecting only a few organs. For others, it may cause serious and even life-threatening problems. In particular lupus nephritis claim a significant number of lives. More than 16,000 Americans develop lupus each year. It is estimated that 500,000 to 1.5 million Americans have been diagnosed with lupus. Current treatments focus
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.